These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33708033)

  • 21. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial.
    Burzotta F; Brancati MF; Trani C; Porto I; Tommasino A; De Maria G; Niccoli G; Leone AM; Coluccia V; Schiavoni G; Crea F
    Trials; 2012 May; 13():55. PubMed ID: 22559260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(12):1-97. PubMed ID: 23074482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Systems Biocompatibility of Coronary Stenting.
    Kolandaivelu K; Rikhtegar F
    Interv Cardiol Clin; 2016 Jul; 5(3):295-306. PubMed ID: 28582028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
    Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial.
    Park SD; Yoon CH; Oh IY; Suh JW; Cho YS; Youn TJ; Choi DJ; Chae IH
    Trials; 2013 Feb; 14():38. PubMed ID: 23394404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving Coronary Stent Technologies - A Glimpse Into the Future.
    Patel S; Patel KB; Patel Z; Konat A; Patel A; Doshi JS; Chokshi P; Patel D; Sharma K; Amdani MM; Shah DB; Dholu U; Patel M
    Cureus; 2023 Mar; 15(3):e35651. PubMed ID: 37009355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution.
    Sakamoto A; Torii S; Jinnouchi H; Virmani R; Finn AV
    Expert Rev Med Devices; 2018 Sep; 15(9):665-682. PubMed ID: 30132713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?
    Weiss AJ; Lorente-Ros M; Correa A; Barman N; Tamis-Holland JE
    Curr Atheroscler Rep; 2022 Sep; 24(9):731-744. PubMed ID: 35821187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stent longitudinal integrity bench insights into a clinical problem.
    Ormiston JA; Webber B; Webster MW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1310-7. PubMed ID: 22136972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Eluting, Bioresorbable Cardiovascular Stents─Challenges and Perspectives.
    Vallejo-Zamora JA; Vega-Cantu YI; Rodriguez C; Cordell GA; Rodriguez-Garcia A
    ACS Appl Bio Mater; 2022 Sep; ():. PubMed ID: 36150217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stents Eluting 6-Mercaptopurine Reduce Neointima Formation and Inflammation while Enhancing Strut Coverage in Rabbits.
    Ruiter MS; van Tiel CM; Doornbos A; Marinković G; Strang AC; Attevelt NJ; de Waard V; de Winter RJ; Steendam R; de Vries CJ
    PLoS One; 2015; 10(9):e0138459. PubMed ID: 26389595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long-term cardiovascular events.
    Yaylak B; Polat F; Onuk T; Akyüz Ş; Çalık AN; Çetin M; Eren S; Mollaalioğlu F; Kolak Z; Durak F; Dayı ŞÜ
    Catheter Cardiovasc Interv; 2023 Dec; 102(7):1186-1197. PubMed ID: 37855201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents.
    Brami P; Fischer Q; Pham V; Seret G; Varenne O; Picard F
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.
    Malenka DJ; Kaplan AV; Lucas FL; Sharp SM; Skinner JS
    JAMA; 2008 Jun; 299(24):2868-76. PubMed ID: 18577731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.